Literature DB >> 27283504

Functional remnant liver assessment predicts liver-related morbidity after hepatic resection in patients with hepatocellular carcinoma.

Shinji Itoh1, Tomoharu Yoshizumi1, Ken Shirabe1, Koichi Kimura1, Hirohisa Okabe1, Norifumi Harimoto1, Toru Ikegami1, Hideaki Uchiyama1, Akihiro Nishie2, Yoshihiko Maehara1.   

Abstract

AIM: We aimed to evaluate whether functional assessment of the future remnant liver is a predictor of postoperative morbidity after hepatic resection in patients with hepatocellular carcinoma (HCC).
METHODS: One hundred forty-six patients who underwent hepatic resection for HCC were enrolled in this study. Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid enhanced MRI (EOB-MRI) analysis for functional liver assessment was carried out before hepatic resection. The signal intensity in the remnant liver was measured and divided by the signal intensity of the major psoas muscle (the liver to major psoas muscle ratio, LMR) for standardization. The remnant liver function was calculated using the formula (LMR on the hepatobiliary phase/LMR on the precontrast image). Computed tomography liver volumetry was also carried out. The remnant functional liver was calculated as the remnant liver volume or volumetric rate × remnant liver function by EOB-MRI.
RESULTS: Morbidities developed in 19 (13.0%) patients. Morbidities associated with the liver occurred in 7 patients (4.7%). There was no mortality during surgery. Median remnant liver function scores using EOB-MRI and remnant functional liver using volumetric rate or volumetry were 1.82 (range, 1.25-2.96), 155.9 (range, 64.7-285.3), and 1027 (range, 369-2148), respectively. Logistic regression analysis identified the remnant functional liver volume as the only independent predictor for liver-related morbidity.
CONCLUSION: Remnant functional liver volume using computed tomography liver volumetry and EOB-MRI was a significantly useful predictor for liver-related morbidity after hepatic resection in patients with HCC.
© 2016 The Japan Society of Hepatology.

Entities:  

Keywords:  EOB-MRI; functional remnant liver; hepatic resection; morbidity

Year:  2016        PMID: 27283504     DOI: 10.1111/hepr.12761

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  5 in total

1.  Slow Gait Speed Is a Risk Factor for Complications After Hepatic Resection.

Authors:  Shinji Itoh; Tomoharu Yoshizumi; Kazuhisa Sakata; Takashi Motomura; Yohei Mano; Takeo Toshima; Norifumi Harimoto; Noboru Harada; Toru Ikegami; Yuji Soejima; Ryuichi Kusaba; Takahide Kamishima; Akihiro Nishie; Yoshihiko Maehara
Journal:  J Gastrointest Surg       Date:  2018-10-08       Impact factor: 3.452

2.  Successful treatment of isolated bile leakage after hepatectomy combination therapy with percutaneous transhepatic portal embolization and bile duct ablation with ethanol: a case report.

Authors:  Norio Kubo; Norifumi Harimoto; Kei Shibuya; Norihiro Ishii; Mariko Tsukagoshi; Takamichi Igarashi; Akira Watanabe; Kenichiro Araki; Masaya Miyazaki; Hiroyuki Kuwano; Ken Shirabe
Journal:  Surg Case Rep       Date:  2018-06-19

Review 3.  Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update.

Authors:  Jia-Zhou Ye; Yan-Yan Wang; Tao Bai; Jie Chen; Bang-De Xiang; Fei-Xiang Wu; Le-Qun Li
Journal:  Oncotarget       Date:  2017-06-27

4.  Post-hepatectomy liver failure after major hepatic surgery: not only size matters.

Authors:  Ulrika Asenbaum; Klaus Kaczirek; Ahmed Ba-Ssalamah; Helmut Ringl; Christoph Schwarz; Fredrik Waneck; Fabian Fitschek; Christian Loewe; Richard Nolz
Journal:  Eur Radiol       Date:  2018-05-16       Impact factor: 5.315

5.  Impact and risk factors for skeletal muscle mass loss after hepatic resection in patients with hepatocellular carcinoma.

Authors:  Shinji Itoh; Tomoharu Yoshizumi; Takahiro Tomiyama; Norifumi Iseda; Akinari Morinaga; Tomonari Shimagaki; Huanlin Wang; Takeshi Kurihara; Yoshihiro Nagao; Takeo Toshima; Noboru Harada; Akihiro Nishie; Kousei Ishigami; Masaki Mori
Journal:  JGH Open       Date:  2021-06-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.